Orchestra BioMed (OBIO) Projected to Post Earnings on Monday

Key Points

• Orchestra BioMed is expected to report its Q2 2025 earnings on August 11, with analysts forecasting a loss of ($0.51) per share.
• In its last quarter, the company posted a loss of ($0.49) per share, falling short of the consensus estimate of ($0.46).
• Current institutional ownership stands at 53.20%, with Bank of America recently increasing its stake by 42.0%.

Orchestra BioMed (NASDAQ:OBIO - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Monday, August 11th. Analysts expect Orchestra BioMed to post earnings of ($0.51) per share for the quarter.

Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.03). The firm had revenue of $0.87 million for the quarter, compared to analyst estimates of $0.39 million. Orchestra BioMed had a negative return on equity of 189.26% and a negative net margin of 2,297.85%. On average, analysts expect Orchestra BioMed to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Orchestra BioMed Price Performance

Shares of NASDAQ OBIO traded up $0.20 during trading hours on Monday, hitting $2.64. 377,489 shares of the stock were exchanged, compared to its average volume of 283,567. The company has a debt-to-equity ratio of 0.85, a quick ratio of 3.34 and a current ratio of 3.35. The company has a market cap of $101.82 million, a PE ratio of -1.48 and a beta of 0.62. The company's fifty day simple moving average is $3.05 and its two-hundred day simple moving average is $3.65. Orchestra BioMed has a 1-year low of $2.37 and a 1-year high of $7.04.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Orchestra BioMed stock. Bank of America Corp DE lifted its position in shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) by 42.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,780 shares of the company's stock after purchasing an additional 7,036 shares during the period. Bank of America Corp DE owned 0.06% of Orchestra BioMed worth $95,000 at the end of the most recent quarter. 53.20% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently issued reports on OBIO shares. HC Wainwright reiterated a "buy" rating on shares of Orchestra BioMed in a research report on Wednesday, April 23rd. Barclays reduced their price target on shares of Orchestra BioMed from $16.00 to $12.00 and set an "overweight" rating on the stock in a research report on Monday, May 5th. Finally, Chardan Capital reiterated a "buy" rating and set a $20.00 price target on shares of Orchestra BioMed in a research report on Tuesday, May 13th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Orchestra BioMed has an average rating of "Buy" and an average target price of $14.00.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.